Diarrhoea News and Research

RSS

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhea in cancer patients, according to results of a phase II/III study in India.

22 Oct 2018

Study finds differences in side-effects experienced by male and female OG cancer patients

Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomized controlled clinical trials of first line chemotherapy in oesophagogastric cancer, finding significant differences in a number of important side-effects experienced by male and female patients.

19 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Innovation Fund Denmark supports research project that aims to fight Clostridium difficile diarrhea

One man's trash is another man's treasure, as the saying goes. If things go to plan, feces from registered and thoroughly tested healthy donors will in a few years be the standard treatment for the bacterium Clostridium difficile at Danish hospitals.

21 Sep 2018

Insulin treatment shows great potential against chronic bowel inflammation

Millions of people take insulin every day to treat their diabetes. But diabetes is not the only disease on which insulin has an effect, it appears.

21 Sep 2018

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy, and tolerability of Ofev (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF).

17 Sep 2018

Research shows how poisonous proteins of Clostridium difficile penetrate intestinal cells

Treating bacterial infections with antibiotics often kills intestinal flora, leading to diarrhoea and inflammation of the gut.

12 Sep 2018

New paper reports conserved collateral susceptibility to antibiotics in E. coli

LSTM's Dr Adam Roberts is a co-author on a new paper published in Nature Communications which reports conserved collateral susceptibility to antibiotics in the human pathogen Escherichia coli.

10 Sep 2018

Fiber strengthens intestinal barrier and counteracts gastrointestinal problems

Similar to patients with Crohn's disease, elderly people with stomach problems have a intestinal barrier that is not functioning optimally.

7 Sep 2018

UniSA researchers unearth potential cure for obesity

It costs the global economy an estimated US$2 trillion annually and has been dubbed a modern day health epidemic, but new research from the University of South Australia has unearthed a possible cure for obesity – and it is as plain as dirt!

31 Aug 2018

WVU professor working to predict, prevent a major cholera outbreak in Yemen

Antar Jutla, associate professor of civil and environmental engineering at West Virginia University, is part of a British-led humanitarian team that is working to predict and prevent a major outbreak of cholera in war-torn Yemen.

28 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Study: Rotavirus vaccination reduces infant diarrhea deaths by 34% in rural Malawi

A major new study has shown that rotavirus vaccination reduced infant diarrhoea deaths by 34% in rural Malawi, a region with high levels of child deaths.

13 Aug 2018

Study: 11% of IBS-D patients suffer from suicidal thinking when their condition is bad

Eleven percent of irritable bowel syndrome with diarrhoea (IBS-D) patients reveal that they suffer from suicidal thinking when their condition is bad, a new study has found.

10 Aug 2018

Clinical trial to use stem cell transplants for treating Crohn's disease

A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease - a painful and chronic intestinal disease which affects at least 115,000 people in the UK.

6 Aug 2018

New vaccine could protect unborn babies from Zika virus

Until recently, the Zika virus was not a priority since it affected relatively few people and the cost of creating a vaccine was estimated at EUR 149-468 million. But the spread of Zika in the Americas and discovery of a link with reduced head size and brain damage in babies of women infected while pregnant changed that.

20 Jul 2018

Step towards an HIV/AIDS vaccine

There has been a four decades long challenge to develop a vaccine against the deadly HIV virus that causes AIDS. Last Saturday the research bore fruit when a team of scientists announced that a trial drug has shown immune response in humans and also protected laboratory monkeys from HIV infection.

9 Jul 2018

HIFU treatment may be as effective as surgery or radiotherapy to destroy prostate tumors

Using high energy ultrasound beams to destroy prostate cancer tumors may be as effective as surgery or radiotherapy, but with fewer side effects.

6 Jul 2018

Late onset of diabetes could be indicative of pancreatic cancer

Onset of pancreas cancer after the age of 50 years could be a sign of development of pancreatic cancer finds a new study.

18 Jun 2018

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis

The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology, 2018, demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis with no severe or serious adverse events.